Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Alix Ventures is a venture capital firm established to invest in early-stage life science startups that are engineering biology to enhance human health. Founded by a team of experienced life science entrepreneurs, the firm is based in the United States and focuses on partnering with accomplished founders to tackle significant challenges in the life sciences sector. The firm has a strong emphasis on supporting startups that are at the intersection of technology and biology, particularly those that can drive patient impact.
Currently, Alix Ventures manages a portfolio of 14 companies, reflecting its commitment to the life sciences field. The firm operates exclusively within the U.S. market and has a clear investment strategy that prioritizes early-stage funding, specifically in the pre-seed, seed, and seed-plus stages. This focus allows Alix Ventures to engage deeply with its portfolio companies, providing not just capital but also strategic guidance and operational support.
Alix Ventures concentrates its investments in the life sciences sector, particularly in the emerging 'TechBio' landscape, which merges technology with biology. The firm seeks to support startups that are developing innovative solutions in drug development, tech-enabled diagnostics, genomic data platforms, and clinical trial platforms. Alix Ventures is particularly interested in companies that can demonstrate a clear patient impact through their products or services.
The firm does not invest in international companies, single indication diagnostics, medical devices, or wellness-related applications. This focused approach allows Alix Ventures to concentrate its resources on startups that align closely with its mission of advancing human health through technology-driven biological solutions. The typical check sizes range from pre-seed to seed-plus, enabling the firm to engage with companies at various stages of their development.
Alix Ventures has built a diverse portfolio of 14 companies, each contributing to advancements in the life sciences sector. Notable companies include:
This portfolio showcases Alix Ventures' commitment to supporting innovative companies that are at the forefront of life sciences and technology integration.
Chas Pulido: Founder & General Partner. Chas has extensive experience in the life sciences sector, having previously founded and scaled multiple startups.
Nick Goldner: Venture Partner. Nick brings a wealth of knowledge in venture capital and has a strong background in supporting early-stage companies.
Mark Pulido: Operating Partner. Mark has a track record of operational excellence in life sciences, focusing on scaling startups effectively.
Brian Fiske: SAB Member - Drug Development. Brian is an expert in drug development, contributing valuable insights to portfolio companies.
Daniel Delubac: SAB Member - Diagnostics/Lab Services. Daniel specializes in diagnostics and lab services, providing guidance on relevant technologies.
Jake Becraft: SAB Member - Syn Bio / CGT. Jake has expertise in synthetic biology and cell and gene therapy, enhancing the firm's investment strategy.
To pitch Alix Ventures, founders should visit their website at alix.vc. The firm prefers pitches that include a clear overview of the startup's mission, market opportunity, and how their technology integrates with biology. While there are no specific application forms, a well-structured deck is essential.
Response times may vary, but founders should expect to hear back within a few weeks. Alix Ventures does not require warm introductions, making it accessible for founders to submit their pitches directly.
In recent months, Alix Ventures has continued to expand its portfolio, focusing on companies that are innovating within the life sciences sector. Notably, they have invested in several startups that are developing solutions in drug development and diagnostics.
On a significant note, Circularis, one of their portfolio companies, was acquired by Ginkgo Bioworks, marking a successful exit for Alix Ventures. This acquisition highlights the firm's ability to identify and support companies with high growth potential in the TechBio landscape.
What are Alix Ventures' investment criteria?
Alix Ventures focuses on early-stage life science companies, particularly those in the TechBio sector. They look for startups that develop innovative solutions in drug development, tech-enabled diagnostics, genomic data platforms, and clinical trial platforms.
How can I pitch to Alix Ventures?
Founders can submit their pitches through the Alix Ventures website at alix.vc. The firm does not provide specific email addresses for pitches.
What makes Alix Ventures different from other investors?
Alix Ventures specializes in the life sciences sector and emphasizes partnerships with accomplished founders. Their focus on the TechBio landscape allows them to support companies that integrate technology with biology for patient impact.
What is the geographic scope of Alix Ventures?
Alix Ventures exclusively invests in companies based in the United States, ensuring a concentrated approach to their investment strategy.
What is the typical check size for investments?
Alix Ventures invests in the pre-seed, seed, and seed-plus stages, which typically involves smaller check sizes that align with early-stage funding needs.
What kind of post-investment involvement does Alix Ventures have?
Alix Ventures actively engages with its portfolio companies, providing operational support and strategic guidance to help them scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.